Reported Earlier, Astrazeneca's Imfinzi (Durvalumab) In Combination With Bacillus Calmette-guérin (BCG) Induction And Maintenance Therapy Has Been Approved In The Us For The Treatment Of Adult Patients With BCG-naïve, High-risk Non-muscle-invasive Bladder Cancer